Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
Featured trial
A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis

A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis

  • 451 views
  • 23 Nov, 2020
  • 1 location
Featured trial
  • 2446 views
  • 23 Nov, 2020
  • 18 locations
Featured trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

  • 816 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Do you suffer from lower back pain?

Do you suffer from lower back pain?

  • 1590 views
  • 08 Nov, 2020
  • 1 location
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and

anti-rheumatic drugs
spondylitis
DMARD
psoriatic plaque
psoriasis
  • 113 views
  • 24 Oct, 2022
  • 98 locations
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis (APEX)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

polyarticular arthritis
anti-rheumatic drugs
spondylitis
DMARD
psoriatic plaque
  • 47 views
  • 25 Oct, 2022
  • 171 locations
A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent (SOLSTICE)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior

polyarticular arthritis
spondylitis
psoriatic plaque
tumour necrosis
rheumatoid nodules
  • 0 views
  • 25 Oct, 2022
  • 87 locations
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic

  • 9 views
  • 07 Oct, 2022
  • 89 locations
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .

  • 0 views
  • 07 Oct, 2022
  • 80 locations
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) (PEAPOD)

The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age

  • 0 views
  • 28 Oct, 2022
  • 31 locations